1、Product Data SheetTacrolimus monohydrateCat. No.: HY-13756ACAS No.: 109581-93-3分式: CHNO分量: 822.03作靶點: Phosphatase; FKBP; Autophagy; Bacterial作通路: Metabolic Enzyme/Protease; Apoptosis; Autophagy; Immunology/Inflammation;Anti-infection儲存式: 4C, protect from light* In solvent : -80C, 6 months; -20C, 1 m

2、onth (protect from light)溶解性數據體外實驗 DMSO : 100 mg/mL (121.65 mM)H2O : 0.1 mg/mL (insoluble)* means soluble, but saturation unknown.SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 1.2165 mL 6.0825 mL 12.1650 mL5 mM 0.2433 mL 1.2165 mL 2.4330 mL10 mM 0.1217 mL 0.6083 mL 1.2165 mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑

3、配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month (protect from light)。-80C 儲存時，請在 6 個內使，-20C 儲存時，請在 1 個內使。體內實驗請根據您的實驗動物和給藥式選擇適當的溶解案。以下溶解案都請先按照 In Vitro 式配制澄清的儲備液，再依次添加助溶劑：為保證實驗結果的可靠性，澄 的儲備液可以根據儲存條件，適當保存；體內實驗的作液，建議您現現配，當天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現沉淀、析出現象，可以通過加熱和/或

4、超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (3.04 mM); Clear solution此案可獲得 2.5 mg/mL (3.04 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolub

5、ility: 2.5 mg/mL (3.04 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲得 2.5 mg/mL (3.04 mM，飽和度未知) 的澄 溶液，此案不適于實驗周 期在半個以上的實驗。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 900 L 油中，混合均勻。BIOLOGICAL ACTIVITY物活性 Tacrolimus monohydrate (FK506 monohydrate) 環(huán)內酯類化合物，Tacrolimus monohydrate 與 FK506 結合蛋 ( FKBP) 結

6、合形成復合物并抑制鈣調神經磷酸酶 (calcineurin phosphatase)，從抑制 T 淋巴細胞信號轉導和 IL-2 轉錄。具有強免疫抑制特性。IC & Target PP2B (calcineurin phosphatase)1Autophagy inducer2體外研究 Tacrolimus monohydrate (FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate) inhibits calcium-dependent events, such as IL-2 gene transcription, N

7、O synthase activation, cell degranulation, and apoptosis.Tacrolimus also potentiates the actions of glucocorticoids and progesterone by binding to FKBPs contained within thehormone receptor complex, preventing degradation. The agent may enhance expression of the TGF-1 gene in afashion analogous to t

8、hat demonstrated for CsA. T cell proliferation in response to ligation of the T cell receptor isinhibited by Tacrolimus1. Treatment with a low concentration of Tacrolimus (FK506,10 g/L) does not significantlyaffect the proliferation of MH3924A cells (P=0.135). Upon treatment with higher concentratio

9、ns of Tacrolimus (100-1,000 g/L), the proliferation of MH3924A cells is significantly enhanced (P0.05). However, whendifferent concentrations of AMD3100 are combined with 100 g/L Tacrolimus, the in vitro proliferation of MH3924Acells is increased (P0.01)3.體內研究 The therapeutic effect of Tacrolimus is

10、 investigated on progression and perpetuation of colitis by administeringTacrolimus to Dextran sulfate sodium (DSS)-treated mice from Days 10 to 16 or to 23. At Days 17 and 24, colon length is significantly shortened, and colon weight is significantly higher in DSS-treated control animals than innor

11、mal animals. In addition, colon weight per unit length in the control group is more than twice that in the normalgroup. While both 7 and 14 d treatment with Tacrolimus significantly suppresses increases in colon weight per unitlength in DSS-treated animals compared with the control group, this treat

12、ment does not actually restore the colonshortening. In addition, this inhibitory effect of Tacrolimus on increases in colon weight per unit length is morepronounced with 14-d than 7-d treatment, as shown by the inhibitory percentages (59% vs. 28%)4.PROTOCOLCell Assay 3 Tumor cell proliferation is de

13、termined by the MTT assay. Briefly, after MH3924A cells have reached the logarithmicgrowth phase, a 0.2-mL cell suspension at 1104 cells/mL is added into each well of a 96-well plate and cultured inDMEM with 10% FBS, 10 g/L vascular endothelial growth factor and 0.1 g/L heparin for 24 h. When adhere

14、nt growthis established, different concentrations of Tacrolimus (10, 100 and 1,000 g/L) , AMD3100 (10, 50 and 100 g/L) andTacrolimus (0 and 100 g/L)+AMD3100 (0, 10, 50 and 100 g/L) are added into the plates. Untreated cells culturedin medium alone are used as controls. After culturing for 48 h, 10 L

15、 MTT (5 g/L) are added, and each well isincubated for 6 h; next, 150 L/well DMSO are added, followed by measurements of the absorbance at 570 mm on aspectrophotometer reader. Each well is measured three times, and each sample is assayed in triplicate3.MCE has not independently confirmed the accuracy

16、 of these methods. They are for reference only.Animal Mice4Administration 4 Six-week-old male C57BL/6J mice are maintained in a temperature- and humidity-controlled room with a 12-h light of 3 www.MedChemEdark cycle. For the multiple dosing study, colitic mice (n=10) are orally administered Tacrolim

17、us at 30 mg/kg for 7 d(Days 10 to 16) or 14 d (Days 10 to 23). Control (n=10) and normal groups (n=5) are administered placebo using thesame regimen. Tacrolimus or placebo is administered at 10 mL/kg. Mice are euthanized by CO2 inhalation on the dayfollowing the final dosing. For the single dosing s

18、tudy, colitic mice are orally administered Tacrolimus at 30 mg/kg orplacebo (n=8) once on Day 7, 10, 17, or 24. Normal mice (n=4) are administered placebo using the same regimen.Mice are euthanized by CO2 inhalation eight hours after dosing4.MCE has not independently confirmed the accuracy of these

19、methods. They are for reference only.戶使本產品發(fā)表的科研獻 Nano Lett. 2019 Jan 9;19(1):124-134. J Extracell Vesicles. 2019 Dec. Cell Syst. 2018 Apr 25;6(4):424-443.e7. Nano Res. 30 June 2018. Theranostics. 2018 Jan 1;8(4):878-893.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Thomson AW, et al. Mode of action of Tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91.2. Vogel KR, et al. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinatesemialdehyde de